Hydroxytyrosol

Phase 1Small molecule

TThe Methodist Hospital Research Institute

Hydroxytyrosol is one of 27 small molecule programs targeting Colorectal Carcinoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Colorectal CarcinomaRecruiting

Colorectal CarcinomaPhase 1

Recruiting

Competition

Competitive Landscape

29 competitors in Colorectal Carcinoma

#DrugCompanyPhaseTrials

Stivarga

Tukysa

Verzenio

Avastin

10 5

Inlyta

PPrism Pharmaceuticals

Glucophage

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

6 8

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

3 9

Eloxatin

Teva

Phase 2

6 10

Tecentriq

Roche

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 1Recruiting

Colorectal Carcinoma

NCT06833866

Clinical

Trials by Indication[1]

Breast Cancer1 trial

Olive Oil for High Risk Breast Cancer Prevention in Women

Completed·TThe Methodist Hospital Research Institute·Phase 2/3·NCT02068092·51 enrolled

Colorectal Carcinoma1 trial

Phase I Trial of 5-Fluorouracil (5FU) -Based Therapy in Combination With Hydroxytyrosol (HT) in Patients With Advanced or Metastatic Colorectal Cancer

Recruiting·TThe Methodist Hospital Research Institute·Phase 1·NCT06833866·33 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Hydroxytyrosol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Hydroxytyrosol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Hydroxytyrosol. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The Methodist Hospital Research Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: TThe Methodist Hospital Research Institute

Hydroxytyrosol

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Breast Cancer1 trial

Colorectal Carcinoma1 trial

References

Drug Info

Quick Facts

Related News